Sunshine Biopharma, Inc. (SBFM) Stock Forecast
SBFM analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $56.00 average of analyst targets
- Upside to target
- +25,125.2% from the latest close
- Next earnings
- November 12, 2026
- 52-week range
- $0.22 – $19.60
SBFM analyst ratings
1 analystsNumber of analysts at each rating.
SBFM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SBFM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.17 | −$0.17 | −$1.90 | +91.0% | 1 |
| Current fiscal year (2026) | −$1.95 | −$1.95 | −$1.95 | −$14.40 | +86.5% | 1 |
| Next fiscal year (2027) | −$0.40 | −$0.40 | −$0.40 | −$1.95 | +79.5% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SBFM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $9.6M | $9.6M | $9.6M | +1.9% | 1 |
| Current fiscal year (2026) | $36.8M | $36.8M | $36.8M | +1.2% | 1 |
| Next fiscal year (2027) | $45.0M | $45.0M | $45.0M | +22.4% | 1 |
SBFM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SBFM revenue: reported and forecast
SBFM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.20 | −$0.20 | −$0.20 | −$0.17 | −15.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$6.30 | −$6.30 | −$6.30 | −$6.30 | −$1.95 | −69.0% | 1 up · 0 down |
| Next fiscal year (2027) | $0.20 | $0.20 | $0.20 | $0.20 | −$0.40 | −300.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SBFM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SBFM beat in 4 of 12.
What analysts expect from SBFM
1 analysts cover Sunshine Biopharma; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $56.00, 25,125.2% above the latest close of $0.22. Analysts expect earnings of −$1.95 per share for 2026, +86.5% from a year earlier. For 2027 the average estimate is −$0.40 per share on revenue of $45.0 million. Sunshine Biopharma beat the EPS estimate in 4 of the last 12 quarters.
Related: SBFM income statement, SBFM key metrics, SBFM chart. See the SBFM stock overview for the latest quote and news.
SBFM forecast FAQ
What is Sunshine Biopharma's price target?
The average analyst price target for Sunshine Biopharma is $56.00, 25,125.2% above the latest close of $0.22.
Is Sunshine Biopharma a buy, hold or sell?
Of 1 analysts covering Sunshine Biopharma, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Sunshine Biopharma's EPS forecast?
Analysts forecast −$1.95 per share for 2026 (range −$1.95 to −$1.95); for 2027 the estimate is −$0.40.
What is Sunshine Biopharma's revenue forecast?
The average revenue estimate for 2026 is $36.8 million, growth of 1.2%; for 2027 it is $45.0 million.
When does Sunshine Biopharma report earnings?
Sunshine Biopharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
Does Sunshine Biopharma usually beat earnings estimates?
Sunshine Biopharma reported EPS at or above the analyst estimate in 4 of the last 12 quarters.